Autologous anti-CD3/anti-EGFR bispecific antibody armed peripheral blood mononuclear cells

{
  "id": "MLC-T-ONC-011399",
  "term": "Autologous anti-CD3/anti-EGFR bispecific antibody armed peripheral blood mononuclear cells",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous peripheral blood mononuclear cells (PBMCs) in which T lymphocytes are coated with a bispecific antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor (EGFR; HER1; ErbB1) and the T-cell surface antigen CD3 and activated ex vivo, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, the autologous anti-CD3/anti-EGFR bispecific antibody armed PBMCs target, bind to and selectively cross-link CD3-expressing T cells and EGFR-expressing tumor cells. This results in the activation of cytotoxic T lymphocytes (CTLs) and selective cytotoxicity towards the EGFR-expressing tumor cells. EGFR, a receptor tyrosine kinase, is overexpressed on the surfaces of various tumor cell types.",
  "synonyms": [
    "autologous anti-CD3/anti-EGFR bispecific antibody armed PBMCs",
    "autologous anti-CD3/EGFR bispecific antibody armed PBMCs",
    "autologous anti-EGFR/anti-CD3 bispecific antibody armed PBMCs",
    "autologous CD3 x EGFR bispecific antibody armed PBMCs",
    "EGFR FPBMC",
    "EGFR fresh PBMC",
    "EGFRBi armed fresh PBMC"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-cd3-anti-egfr-bispecific-antibody-armed-peripheral-blood-cells/"
}